The present invention relates to a transdermal therapeutic system for the cutaneous administration of phenprocoumon, comprising an active-substance-impermeable backing layer, an adhesive matrix layer and optionally a removable protective layer, the adhesive matrix layer containing phenprocoumon and at least one matrix polymer, and the content of phenprocoumon in the matrix polymer being ≤7.5 wt. %. By virtue of the low load, it is ensured that the system releases the active ingredient substantially in high release rates, because high thermodynamic activity of the active ingredient is achieved. The present invention also relates to a method for producing a corresponding transdermal therapeutic system.

The present disclosure relates to methods of treating cancer and, more particularly, an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, in a dosage form for transdermal delivery in the treatment of cancer.

A medicinal composition containing a scopolamine salt and/or a hydrate thereof, polyvinylpyrrolidone, and a base. The medicinal composition is excellent in terms of absorption of the drug into the living body and chemical stability thereof.

The present disclosure relates to a transdermal drug delivery device, also known as a transdermal patch that can be worn by the user anywhere the person travels throughout the day. The transdermal patch is characterized in that it is a single-layered patch comprising an liposomal emulsion carrying a drug to be administered and an adhesive which are both incorporated into a polymer or polymeric matrix. The liposomal emulsion within the single-layered transdermal patch allows the drug that is to be administered to be spread throughout the entire surface area of the transdermal patch.

Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.

Described herein are examples of patches which include a hydrogel having an active homeopathic ingredient dissolved therein. The active homeopathic ingredient Berberis vulgaris is dissolved in the hydrogel and is effective at treating molluscum contagiosum. The patches are cured and shaped so that the active ingredient kills the virus over time when the patch is in contact with an infected area. The patches temporarily adhere to the skin and are effective at curing and preventing the spread of viral skin infection, both to other people and to other parts of the infected person's body. The patches may be packaged and sold as an over-the-counter homeopathic product.

A patch (10) comprising: a nonwoven fabric (1); and an adhesive layer (2) on the nonwoven fabric (1), wherein the adhesive layer (2) comprises a cool feeling agent, a local anesthetic and/or an anti-inflammatory analgesic, and water, and the adhesive layer (2) has a maximum thickness of 0.50 mm or more.

The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

The present invention relates to transdermal therapeutic systems for the transdermal administration of rotigotine containing a therapeutically effective amount of rotigotine base in a self-adhesive layer structure that includes a backing layer and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase formed from a polymer or a polymer mixture along with an inner phase that includes rotigotine base and a polymer mixture including polyvinylpyrrolidone having a K-Value of at least 80 and at least one further hydrophilic polymer selected from the polymer groups: copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The inner phase forms dispersed deposits in the outer phase. The inventive transdermal therapeutic systems optionally include a skin contact layer.